Dear Colleagues,
The Multipurpose Prevention Technologies (MPTs) field is steadily evolving and expanding. Provided below are links to recent publications, media articles, and other resources relevant to MPTs to keep you up-to-date. Please note that contents are neither endorsed by nor necessarily represent the views of the Initiative for Multipurpose Prevention Technologies (IMPT), and that due to publication copyright and permissions restrictions, full-text versions of resources may not be publicly available. If you have a resource to include in our next issue, please send to Vanetta Thomas at vthomas@cami-health.org. Previous issues are available on the CAMI Health website.
Best,
IMPT Secretariat Staff
|
|
Announcements
ESC Congress
- The IMPT Secretariat staff is happy to share with you all our ePoster that was recently presented at the 14th Congress of the European Society of Contraception and Reproductive Health. To view, click here.
Upcoming Webinar - The Health Communication Capacity Collaborative (HC3) is hosting a the following webinar:
W
hen the Evidence is Not Enough: Hormonal Contraception and HIV. Tuesday, May 17, 2016, 9-10AM EDT to discuss the
strategic framework they designed to assist governments in developing a communication strategy and to guide the development of social and behavior change communication (SBCC) materials and activities focused on hormonal contraception and HIV.
To register click
here
.
|
Journal Articles
Biomarkers and biometric measures of adherence to use of ARV-based vaginal rings. Stalter, R.M., Moench, T.R., MacQueen, K.M., Tolley, E.E., Owen, D.H. (2016, May). Journal of the International AIDS Society 19(1).
Combination pod-intravaginal ring delivers antiretroviral agents for HIV prophylaxis: pharmacokinetic evaluation in an ovine model. Moss, J.A., Butkyavichene, I., Churchman, S.A., Gunawardana, M., Fanter, R., Miller, C.S., ...& Baum, M.M. (2016, May). Antimicrobial Agents and Chemotherapy, 60(5).
Triple combination MPT vaginal microbicide using curcumin and efavirenz loaded lactoferrin nanoparticles
. Lakshmi, Y.S., Kuman, P., Kishore, G., Bhaskar, C., & Kondapi, A.K. (2016, May). Scientific Reports, 6, 25479.
|
The Prevention Innovation Program III (PIP) encourages research applications in Non-vaccine Biomedical Prevention (nBP) research. The PIP is intended to support high-risk/innovative research and development efforts to establish and maintain a sustainable pipeline for the prevention of HIV acquisition/transmission.
USAID is seeking applicants for two of four cooperative agreements aiming to address one or both of the following objectives: (1) Expedite activities required for licensure and market introduction of a dapivirine ring product and bridging opportunities to progress toward licensure of a next-generation ring product (e.g. 90 days or more); (2) Support development and optimization of systemic microbicide or multipurpose prevention technologies (MPTs).
USAID is seeking applicants for opportunities to co-create, co-design, co-invest, and collaborate in the research, development, piloting, testing, and scaling of innovative, practical and cost-effective interventions to address the most pressing problems in global health. Organizations and companies are invited to participate with USAID, in cooperation with its partners, to generate novel tools and approaches that accelerate and sustain improved health outcomes in developing countries.
|
|
|
|
|
